Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning
What's known on the subject? and What does the study add? Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost‐effective. Prostate HistoScanning™ (PH...
Saved in:
| Published in | BJU international Vol. 110; no. 1; pp. 28 - 35 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.07.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1464-4096 1464-410X 1464-410X |
| DOI | 10.1111/j.1464-410X.2011.10734.x |
Cover
| Abstract | What's known on the subject? and What does the study add?
Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost‐effective.
Prostate HistoScanning™ (PHS) is an ultrasound‐based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open ‘unblinded’ phase of a European multicentre study. The prospective ‘blind’ phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging.
OBJECTIVE
•
To evaluate the ability of prostate HistoScanning™ (PHS) an ultrasound (US)‐based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology.
PATIENT AND METHODS
•
In all, 31 patients with organ‐confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres.
•
Before RP three‐dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3–4 mm.
•
Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool.
•
In this report we evaluate data obtained from a planned open study phase. The second phase of the study is ‘blinded’, and currently in progress.
RESULTS
•
31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination.
•
PHS detected cancer ≥0.20 mL in 25/27 prostates (sensitivity 93%).
•
In all, 23 patients had an index focus ≥0.5 mL at pathology, of which 21 were identified as ≥0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥0.5 mL by the embedded tool (sensitivity 83%).
•
In 27 patients, histological analysis found 32 cancerous foci ≥0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥0.2 mL within a sextant.
CONCLUSIONS
•
PHS has the ability to identify and locate prostate cancer and consequently may aid in pre‐treatment and pre‐surgical planning.
•
In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores.
•
However further verification from the results of the blinded phase of this study are awaited. |
|---|---|
| AbstractList | What's known on the subject? and What does the study add?
Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost‐effective.
Prostate HistoScanning™ (PHS) is an ultrasound‐based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open ‘unblinded’ phase of a European multicentre study. The prospective ‘blind’ phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging.
OBJECTIVE
•
To evaluate the ability of prostate HistoScanning™ (PHS) an ultrasound (US)‐based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology.
PATIENT AND METHODS
•
In all, 31 patients with organ‐confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres.
•
Before RP three‐dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3–4 mm.
•
Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool.
•
In this report we evaluate data obtained from a planned open study phase. The second phase of the study is ‘blinded’, and currently in progress.
RESULTS
•
31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination.
•
PHS detected cancer ≥0.20 mL in 25/27 prostates (sensitivity 93%).
•
In all, 23 patients had an index focus ≥0.5 mL at pathology, of which 21 were identified as ≥0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥0.5 mL by the embedded tool (sensitivity 83%).
•
In 27 patients, histological analysis found 32 cancerous foci ≥0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥0.2 mL within a sextant.
CONCLUSIONS
•
PHS has the ability to identify and locate prostate cancer and consequently may aid in pre‐treatment and pre‐surgical planning.
•
In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores.
•
However further verification from the results of the blinded phase of this study are awaited. What's known on the subject? and What does the study add? Prostate cancer is one of the few solid-organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost-effective. Prostate HistoScanning(™) (PHS) is an ultrasound-based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open 'unblinded' phase of a European multicentre study. The prospective 'blind' phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging.UNLABELLEDWhat's known on the subject? and What does the study add? Prostate cancer is one of the few solid-organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost-effective. Prostate HistoScanning(™) (PHS) is an ultrasound-based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open 'unblinded' phase of a European multicentre study. The prospective 'blind' phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging.To evaluate the ability of prostate HistoScanning(™) (PHS) an ultrasound (US)-based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology.OBJECTIVETo evaluate the ability of prostate HistoScanning(™) (PHS) an ultrasound (US)-based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology.In all, 31 patients with organ-confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. Before RP three-dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3-4 mm. Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. In this report we evaluate data obtained from a planned open study phase. The second phase of the study is 'blinded', and currently in progress.PATIENT AND METHODSIn all, 31 patients with organ-confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. Before RP three-dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3-4 mm. Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. In this report we evaluate data obtained from a planned open study phase. The second phase of the study is 'blinded', and currently in progress.31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. PHS detected cancer ≥ 0.20 mL in 25/27 prostates (sensitivity 93%). In all, 23 patients had an index focus ≥ 0.5 mL at pathology, of which 21 were identified as ≥ 0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥ 0.5 mL by the embedded tool (sensitivity 83%). In 27 patients, histological analysis found 32 cancerous foci ≥ 0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥ 0.2 mL within a sextant.RESULTS31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. PHS detected cancer ≥ 0.20 mL in 25/27 prostates (sensitivity 93%). In all, 23 patients had an index focus ≥ 0.5 mL at pathology, of which 21 were identified as ≥ 0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥ 0.5 mL by the embedded tool (sensitivity 83%). In 27 patients, histological analysis found 32 cancerous foci ≥ 0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥ 0.2 mL within a sextant.PHS has the ability to identify and locate prostate cancer and consequently may aid in pre-treatment and pre-surgical planning. In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. However further verification from the results of the blinded phase of this study are awaited.CONCLUSIONSPHS has the ability to identify and locate prostate cancer and consequently may aid in pre-treatment and pre-surgical planning. In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. However further verification from the results of the blinded phase of this study are awaited. What's known on the subject? and What does the study add? Prostate cancer is one of the few solid-organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost-effective. Prostate HistoScanning(™) (PHS) is an ultrasound-based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open 'unblinded' phase of a European multicentre study. The prospective 'blind' phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging. To evaluate the ability of prostate HistoScanning(™) (PHS) an ultrasound (US)-based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology. In all, 31 patients with organ-confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. Before RP three-dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3-4 mm. Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. In this report we evaluate data obtained from a planned open study phase. The second phase of the study is 'blinded', and currently in progress. 31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. PHS detected cancer ≥ 0.20 mL in 25/27 prostates (sensitivity 93%). In all, 23 patients had an index focus ≥ 0.5 mL at pathology, of which 21 were identified as ≥ 0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥ 0.5 mL by the embedded tool (sensitivity 83%). In 27 patients, histological analysis found 32 cancerous foci ≥ 0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥ 0.2 mL within a sextant. PHS has the ability to identify and locate prostate cancer and consequently may aid in pre-treatment and pre-surgical planning. In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. However further verification from the results of the blinded phase of this study are awaited. What's known on the subject? and What does the study add? Prostate cancer is one of the few solid-organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost-effective. Prostate HistoScanning(TM) (PHS) is an ultrasound-based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open 'unblinded' phase of a European multicentre study. The prospective 'blind' phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging. OBJECTIVE * To evaluate the ability of prostate HistoScanning(TM) (PHS) an ultrasound (US)-based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology. PATIENT AND METHODS * In all, 31 patients with organ-confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. * Before RP three-dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3-4 mm. * Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. * In this report we evaluate data obtained from a planned open study phase. The second phase of the study is 'blinded', and currently in progress. RESULTS * 31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. * PHS detected cancer ≥0.20 mL in 25/27 prostates (sensitivity 93%). * In all, 23 patients had an index focus ≥0.5 mL at pathology, of which 21 were identified as ≥0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥0.5 mL by the embedded tool (sensitivity 83%). * In 27 patients, histological analysis found 32 cancerous foci ≥0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥0.2 mL within a sextant. CONCLUSIONS * PHS has the ability to identify and locate prostate cancer and consequently may aid in pre-treatment and pre-surgical planning. * In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. * However further verification from the results of the blinded phase of this study are awaited. |
| Author | Moore, Caroline M. Braeckman, Johan Stenzl, Arnulf Zát'ura, Frantiŝek Peltier, Alexandre Nir, Dror Treurnicht, Karien Simmons, Lucy A.M. Emberton, Mark Autier, Philippe Romic, Imre Walker, Tara |
| Author_xml | – sequence: 1 givenname: Lucy A.M. surname: Simmons fullname: Simmons, Lucy A.M. – sequence: 2 givenname: Philippe surname: Autier fullname: Autier, Philippe – sequence: 3 givenname: Frantiŝek surname: Zát'ura fullname: Zát'ura, Frantiŝek – sequence: 4 givenname: Johan surname: Braeckman fullname: Braeckman, Johan – sequence: 5 givenname: Alexandre surname: Peltier fullname: Peltier, Alexandre – sequence: 6 givenname: Imre surname: Romic fullname: Romic, Imre – sequence: 7 givenname: Arnulf surname: Stenzl fullname: Stenzl, Arnulf – sequence: 8 givenname: Karien surname: Treurnicht fullname: Treurnicht, Karien – sequence: 9 givenname: Tara surname: Walker fullname: Walker, Tara – sequence: 10 givenname: Dror surname: Nir fullname: Nir, Dror – sequence: 11 givenname: Caroline M. surname: Moore fullname: Moore, Caroline M. – sequence: 12 givenname: Mark surname: Emberton fullname: Emberton, Mark |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26042625$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22093966$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV2L1DAUhoOsuF_-BSmIsBdOPUnTtL0R3HV1lYUVXGG9Cqdpqhky6Zik7My_38zXCqOCvWly8pyTvk-PyYEbnCYko5DT9LyZ5pQLPuEU7nIGlOYUqoLniyfk6PHgYLeGRhyS4xCmAKkgymfkkDFoikaII_L9vY5aRTO415kdFFoTcLXL0HWZ-okeVdR-Vxz6bO6HEDHqTKFT2mftMvuyK12ZEIev6cAZ9-OUPO3RBv18-z4htx8uby-uJtc3Hz9dvLueqJIyPhEAGmqoRSu0Lkpa91VX8a5SPUXokLdQAULVFQVjqEVXVoL3jWC8VClZW5yQZjN2dHNc3qO1cu7NDP1SUpArW3IqVyJkkrKQK1tybUsuUu_ZpjeF-jXqEOXMBKWtRaeHMSSuYHUjaCUS-nIPnQ6jdymYpFXJyoRxlqgXW2psZ7p7_JKd7wS82gIYkuzeJ4km_OYEcCZYmbi3G04lt8HrXioT1_8gejT2L9Hu9qPVewP-beWP1u3d98bq5X_3yfPP39bL4gEvIsc2 |
| CODEN | BJINFO |
| CitedBy_id | crossref_primary_10_1007_s00345_014_1330_5 crossref_primary_10_1016_j_acuro_2013_01_003 crossref_primary_10_2147_RRU_S291963 crossref_primary_10_1089_end_2013_0419 crossref_primary_10_1007_s00345_013_1080_9 crossref_primary_10_1002_nbm_3002 crossref_primary_10_1111_bju_12023 crossref_primary_10_1016_j_eururo_2012_08_026 crossref_primary_10_1111_iju_12170 crossref_primary_10_1007_s00092_016_0962_8 crossref_primary_10_1007_s40137_014_0077_7 crossref_primary_10_1016_j_prnil_2018_03_005 crossref_primary_10_1007_s00345_013_1211_3 crossref_primary_10_1016_j_urology_2012_08_072 crossref_primary_10_1038_s41391_018_0094_1 crossref_primary_10_1016_j_eururo_2014_01_001 crossref_primary_10_1097_MOU_0b013e32835d4dc8 crossref_primary_10_1007_s00345_013_1172_6 crossref_primary_10_1007_s13193_016_0584_3 crossref_primary_10_1016_j_tranon_2014_11_005 crossref_primary_10_1100_2012_193213 crossref_primary_10_1007_s00092_016_1218_3 crossref_primary_10_1016_j_urolonc_2014_09_009 crossref_primary_10_1016_j_euf_2015_06_003 crossref_primary_10_19163_1994_9480_2018_1_65__122_124 crossref_primary_10_1038_nrurol_2013_129 crossref_primary_10_1007_s10462_020_09920_8 crossref_primary_10_1007_s11934_017_0747_y crossref_primary_10_1159_000440814 crossref_primary_10_4137_BECB_S34255 crossref_primary_10_5301_RU_2013_11667 crossref_primary_10_1111_iju_12159 crossref_primary_10_1097_MOU_0000000000000041 crossref_primary_10_1097_MOU_0000000000000162 crossref_primary_10_1007_s15006_014_3814_z crossref_primary_10_1016_j_acuroe_2013_01_003 crossref_primary_10_1016_j_eururo_2012_09_033 crossref_primary_10_3238_arztebl_2015_0605 crossref_primary_10_1111_bju_12568 crossref_primary_10_1007_s00120_012_3103_3 crossref_primary_10_1016_j_urology_2014_06_050 crossref_primary_10_1007_s00120_014_3731_x crossref_primary_10_1007_s00345_014_1434_y crossref_primary_10_1016_j_clon_2013_05_002 crossref_primary_10_1016_j_euf_2017_07_001 crossref_primary_10_1038_nrclinonc_2012_136 crossref_primary_10_47470_0044_197X_2022_66_6_549_554 crossref_primary_10_1016_j_acra_2014_04_015 crossref_primary_10_1177_107327481302000305 crossref_primary_10_1177_2051415813489682 crossref_primary_10_1007_s11934_012_0280_y crossref_primary_10_1007_s00345_015_1555_y crossref_primary_10_21886_2308_6424_2023_11_2_132_141 crossref_primary_10_1016_j_eururo_2013_05_048 crossref_primary_10_3389_fonc_2022_905087 crossref_primary_10_1016_j_tranon_2017_06_006 crossref_primary_10_1007_s00120_014_3533_1 crossref_primary_10_1016_j_cct_2013_11_009 crossref_primary_10_1186_s12894_015_0072_z crossref_primary_10_1007_s00261_013_0018_4 crossref_primary_10_1016_j_brachy_2022_02_003 crossref_primary_10_3390_diagnostics13132283 crossref_primary_10_1007_s00345_021_03684_8 crossref_primary_10_1016_j_urolonc_2015_07_004 |
| Cites_doi | 10.3747/co.v17i0.713 10.1016/j.eururo.2007.08.006 10.1056/NEJMoa0908127 10.7326/0003-4819-138-1-200301070-00012-w1 10.1016/j.juro.2006.08.007 10.1016/j.ijrobp.2003.10.014 10.1038/nrclinonc.2009.18 10.3109/10929080802364645 10.1002/cncr.23575 10.1007/s11934-007-0005-9 10.1111/j.1464-410X.2007.07232.x 10.1016/j.urolonc.2009.03.032 10.1200/JCO.2009.24.4533 10.1016/j.urolonc.2008.09.030 10.1016/S0022-5347(01)65201-7 10.1111/j.1464-410X.2008.07878.x 10.1111/j.1464-410X.2010.09808.x 10.1016/j.urolonc.2008.03.005 10.1016/j.urology.2010.05.022 |
| ContentType | Journal Article |
| Copyright | 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL 2015 INIST-CNRS 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
| Copyright_xml | – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 ADTOC UNPAY |
| DOI | 10.1111/j.1464-410X.2011.10734.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Calcium & Calcified Tissue Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 35 |
| ExternalDocumentID | 10.1111/j.1464-410x.2011.10734.x 3908411841 22093966 26042625 10_1111_j_1464_410X_2011_10734_x BJU10734 |
| Genre | article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5124-600e08086b6ee3518f7d74d7cf1a0da4b070a07d3322ae6d5764f96245c409b3 |
| IEDL.DBID | UNPAY |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Tue Aug 19 18:12:47 EDT 2025 Fri Sep 05 12:23:34 EDT 2025 Fri Jul 25 05:39:29 EDT 2025 Mon Jul 21 06:04:38 EDT 2025 Mon Jul 21 09:15:42 EDT 2025 Wed Oct 01 04:28:52 EDT 2025 Thu Apr 24 23:07:20 EDT 2025 Sun Sep 21 06:28:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Nephrology detection Urinary system disease Prostate disease HistoScanning Malignant tumor Diagnosis Male genital diseases Prostate cancer Urology Cancer |
| Language | English |
| License | CC BY 4.0 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5124-600e08086b6ee3518f7d74d7cf1a0da4b070a07d3322ae6d5764f96245c409b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2011.10734.x |
| PMID | 22093966 |
| PQID | 1752589642 |
| PQPubID | 1026371 |
| PageCount | 8 |
| ParticipantIDs | unpaywall_primary_10_1111_j_1464_410x_2011_10734_x proquest_miscellaneous_1032896176 proquest_journals_1752589642 pubmed_primary_22093966 pascalfrancis_primary_26042625 crossref_citationtrail_10_1111_j_1464_410X_2011_10734_x crossref_primary_10_1111_j_1464_410X_2011_10734_x wiley_primary_10_1111_j_1464_410X_2011_10734_x_BJU10734 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2012 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: July 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
| References | 1997; 157 2010; 76 2011; 107 2003; 138 2010 2010; 28 2010; 17 2004; 59 2007; 8 2008; 26 2006; 176 2010; 362 2008; 13 2005 2009; 6 2008; 113 2007; 52 2008; 102 2008; 101 2011; 29 2009; 27 e_1_2_8_16_2 e_1_2_8_18_2 e_1_2_8_19_2 e_1_2_8_12_2 e_1_2_8_13_2 e_1_2_8_14_2 e_1_2_8_15_2 e_1_2_8_9_2 Klotz L (e_1_2_8_17_2) 2010; 17 e_1_2_8_2_2 e_1_2_8_4_2 e_1_2_8_3_2 e_1_2_8_6_2 e_1_2_8_5_2 e_1_2_8_8_2 e_1_2_8_7_2 e_1_2_8_20_2 e_1_2_8_10_2 e_1_2_8_21_2 e_1_2_8_11_2 e_1_2_8_22_2 |
| References_xml | – volume: 13 start-page: 255 year: 2008 end-page: 64 article-title: Real‐time MRI‐TRUS fusion for guidance of targeted prostate biopsies publication-title: Comput Aided Surg – volume: 76 start-page: 1025 year: 2010 end-page: 33 article-title: Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer publication-title: Urology – volume: 26 start-page: 506 year: 2008 end-page: 10 article-title: Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy publication-title: Urol Oncol – volume: 28 start-page: 302 year: 2010 end-page: 7 article-title: Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7 publication-title: Urol Oncol – volume: 362 start-page: 1192 year: 2010 end-page: 202 article-title: Effect of dutasteride on the risk of prostate cancer publication-title: N Engl J Med – year: 2005 – volume: 17 start-page: S11 issue: 2 year: 2010 end-page: 7 article-title: Active surveillance for prostate cancer: patient selection and management publication-title: Curr Oncol – volume: 101 start-page: 293 year: 2008 end-page: 8 article-title: Computer‐aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer publication-title: BJU Int – volume: 157 start-page: 559 year: 1997 end-page: 62 article-title: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications publication-title: J Urol – volume: 59 start-page: 386 year: 2004 end-page: 91 article-title: Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients publication-title: Int J Radiat Oncol Biol Phys – volume: 138 start-page: W1 year: 2003 end-page: 12 article-title: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration publication-title: Ann Intern Med – volume: 176 start-page: 2432 year: 2006 end-page: 7 article-title: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings publication-title: J Urol – volume: 107 start-page: 1411 year: 2011 end-page: 8 article-title: Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging publication-title: BJU Int – volume: 8 start-page: 190 year: 2007 end-page: 6 article-title: Optimal cost‐effective staging evaluations in prostate cancer publication-title: Curr Urol Rep – volume: 113 start-page: 286 year: 2008 end-page: 92 article-title: Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance publication-title: Cancer – volume: 102 start-page: 1560 year: 2008 end-page: 5 article-title: The accuracy of transrectal ultrasonography supplemented with computer‐aided ultrasonography for detecting small prostate cancers publication-title: BJU Int – volume: 29 start-page: 295 year: 2011 end-page: 301 article-title: Contrast‐enhanced transrectal ultrasound (CE‐TRUS) with cadence‐contrast pulse sequence (CPS) technology for the identification of prostate cancer publication-title: Urol Oncol – volume: 27 start-page: 4935 year: 2009 end-page: 6 article-title: Evidence‐based medicine, conscience‐based medicine, and the management of low‐risk prostate cancer publication-title: J Clin Oncol – volume: 52 start-page: 1309 year: 2007 end-page: 22 article-title: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature publication-title: Eur Urol – year: 2010 – volume: 6 start-page: 197 year: 2009 end-page: 206 article-title: Is it time to consider a role for MRI before prostate biopsy? publication-title: Nat Rev Clin Oncol – volume: 17 start-page: S11 issue: 2 year: 2010 ident: e_1_2_8_17_2 article-title: Active surveillance for prostate cancer: patient selection and management publication-title: Curr Oncol doi: 10.3747/co.v17i0.713 – ident: e_1_2_8_7_2 doi: 10.1016/j.eururo.2007.08.006 – ident: e_1_2_8_3_2 doi: 10.1056/NEJMoa0908127 – ident: e_1_2_8_13_2 doi: 10.7326/0003-4819-138-1-200301070-00012-w1 – ident: e_1_2_8_18_2 doi: 10.1016/j.juro.2006.08.007 – ident: e_1_2_8_6_2 doi: 10.1016/j.ijrobp.2003.10.014 – ident: e_1_2_8_14_2 – ident: e_1_2_8_15_2 doi: 10.1038/nrclinonc.2009.18 – ident: e_1_2_8_16_2 doi: 10.3109/10929080802364645 – ident: e_1_2_8_2_2 doi: 10.1002/cncr.23575 – ident: e_1_2_8_20_2 doi: 10.1007/s11934-007-0005-9 – ident: e_1_2_8_10_2 doi: 10.1111/j.1464-410X.2007.07232.x – ident: e_1_2_8_12_2 – ident: e_1_2_8_21_2 doi: 10.1016/j.urolonc.2009.03.032 – ident: e_1_2_8_9_2 doi: 10.1200/JCO.2009.24.4533 – ident: e_1_2_8_4_2 doi: 10.1016/j.urolonc.2008.09.030 – ident: e_1_2_8_5_2 doi: 10.1016/S0022-5347(01)65201-7 – ident: e_1_2_8_11_2 doi: 10.1111/j.1464-410X.2008.07878.x – ident: e_1_2_8_19_2 doi: 10.1111/j.1464-410X.2010.09808.x – ident: e_1_2_8_8_2 doi: 10.1016/j.urolonc.2008.03.005 – ident: e_1_2_8_22_2 doi: 10.1016/j.urology.2010.05.022 |
| SSID | ssj0014665 |
| Score | 2.3216882 |
| Snippet | What's known on the subject? and What does the study add?
Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic... What's known on the subject? and What does the study add? Prostate cancer is one of the few solid-organ cancers in which imaging is not used in the diagnostic... |
| SourceID | unpaywall proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 28 |
| SubjectTerms | Aged Biological and medical sciences detection diagnosis Gynecology. Andrology. Obstetrics Histology HistoScanning Humans Localization Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Patients Prostate - diagnostic imaging Prostate - pathology Prostate cancer Prostatectomy Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Tumor Burden Tumors Tumors of the urinary system Ultrasonic imaging Ultrasonography Urinary tract. Prostate gland |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS-wwEB7EBz0iXs7xHOuNCD6eLk2bNttHr4igiBfY8xSSNH1x6S7uLl5-vZOkW-kiIgfflmynpNOZyTfN5BuAg7TLOaIGHXJKkxDXaxkqmVPMUmheaszFYmoPOF9eZef37KKX9ur6J3sWxvNDNB_crGe4eG0dXKrRrJOzkNGo55k4MZFJWMfiSZqkbsf2pmGSwktdV0kvgrC9XdTz4Y1aK9XyUI5QaaXvdvERHF2CxUk1lC9Pst9vI123VJ2twsP0IX2FykNnMlYd_TrD__g9WliDlRrRkkNvguswZ6qfsHBZ79n_gn8nZuzqvaq_xK2cdQERkVVB9DtftB8clGRoD6IgBCbaWuQjUS_kejrkWE1utW-0tAF3Z6d3x-dh3dAh1IgrWIjgyiBC7WYqMyZJabfkBWcF1yWVUSGZwvgjI14kGGWkyQrMhViZZzFLNb4zlfyG-WpQmU0gBS4xKspllJWa5Zg0ZlIyU2L4kV2joyIAPn13Qtdk57bnRl-0kh4mrOKEVZxwihPPAdBGcugJP74gs9cyj0YQk0XL-J8GsDO1F1HHiJFA4BanOHMWB7Df_I3ebbdsZGUGE7zG0h3miDKzAP54O3u_eRzlCWarAcSN4X0y5eeZKXNnVl9-RnF0ce9-bv235Db8wPG62HkH5sePE7OLkG6s9pyzvgED5DiP priority: 102 providerName: Wiley-Blackwell |
| Title | Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10734.x https://www.ncbi.nlm.nih.gov/pubmed/22093966 https://www.proquest.com/docview/1752589642 https://www.proquest.com/docview/1032896176 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2011.10734.x |
| UnpaywallVersion | publishedVersion |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1464-410X dateEnd: 20241004 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-410X databaseCode: ABDBF dateStart: 19990101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-410X databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1464-410X databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Za9wwEB7CBnpQeh9u00WFPtYby5al9WN6hBDIEtosbJ6MrOOli9cku3TTX9-RJTt1KCWUvtmyZcuj0cz3WaMRwPt8KgSiBhULSrMY_bWMK1lQZCm0sAq5WErdAueTGT-as-NFvtiBWbcWxueH6H-4uZHR2ms3wBttvZ3f_y0eh3EWM5osfDZOJDMZmyCm3OVuwmkEu_PZ6cG5X2KENyYF74-x0jC0J5RuB48a-KsHjbxE0Vm_58WfQOl9uLupG3n1Qy6XQ7zbOqzDR7DqPtXHqXyfbNbVRP28kQXy_8niMTwM2JYceGV8Ajumfgp3TsLs_TM4_2zWbeRX_YG0PjSEEhFZa6KuM0f7wpUljVuSgmCYKKebF6S6IqddUZvf5JvyWy49h7PDL2efjuKwtUOsEGGwGDvHIFad8oobk-V0aoUWTAtlqUy0ZBVaIpkInaG9kYZrZEXMFjxlucI-rLIXMKpXtXkFRKOzqZJCJtwqViB95FIyY9EQyalRiY5AdP1XqpD23O2-sSwH9IeVTnClE1zZCq7cRkD7mo1P_XGLOuOBivQVkTa63P95BHudzpTBWlyWCOHSHFvO0gje9ZdxnLvJG1mb1QbvcYkPC8SbPIKXXteuH54mRYa8NYK0V76_NHl7o8miVa1bf2P58XjeHr7-l9e9gXt4GiKe92C0vtiYt4jr1tUYGc3XdByG7C848j5C |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dT9swED8hJsGmia9tLHx6Eo-kihMnbh7Hl8pHEWJFKk-W4zgvq9IKWgH763e206BUCCHEW5X6Iudyd_5dfP4dwF7c5hxRg_I5pZGP67X0M5lSzFJoWijMxUJqDjh3L5PODTvrx_2qHZA5C-P4IeoPbsYzbLw2Dm4-SM96OfMZDfqOihMzmYi1EFB-Mtt1xkuPrmsuKRxr-0o6GQTuzbKeF-_UWKu-juQ9qq1w_S5eAqRfYHFSjuTTgxwMmljXLlYnyzCYPqarUfnbmoyzlvo3wwD5QXpYgaUK1JLfzgpXYU6Xa7DQrbbtv8HtkR7bkq9yn9jFs6ohIrLMiXqmjHYXhwUZmbMoiIKJMkZ5R7IncjW9ZIlN_ijXa-k79E6Oe4cdv-rp4CuEFsxHfKURpLaTLNE6imm74DlnOVcFlUEuWYYhSAY8jzDQSJ3kmA6xIk1CFit8aVn0A-bLYal_AslxlcmCVAZJoViKeWMiJdMFRiDZ1irIPeDTlydUxXdu2m4MRCPvYcIoThjFCas48egBrSVHjvPjDTI7DfuoBTFfNKT_sQdbU4MRVZi4F4jdwhhnzkIPftV_o4ObXRtZ6uEExxjGwxSBZuLBujO055uHQRphwupBWFveK1N-nJkyt3b15mcUB2c39ufGuyV3YbHT616Ii9PL8034jGOq2uctmB_fTfQ2IrxxtmM99z-RPTyr |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hIhUQ4lkgUIqROJJVnDj25giUVSm0qqCVlpPl-HHpKhu1u6Ll1zO2s6myqlCFuEWJJ3KceXyTjL8BeFeOhUDUoFNBaZFivFZprSqKWQqtnMZcLKd-g_PBId87YfvTctrVP_m9MJEfov_g5i0j-Gtv4K1x60bOUkazaWTixESmYCPEk7cZx2TLA6TvPZUUjg1tJaMM4vZhVc-1dxqEqvutOsdVc7HdxXV49B7cWTatuvylZrMh1A2xavIQTldPGUtUTkfLRT3Sv9cIIP_PMjyCBx2kJR-iDj6GW7Z5ApsH3U_7p_Bz1y5CwVfznoTQ2VUQEdUYoq8Io-PJuSOt34mCGJhor5JnpL4kR6tTgdbkh46dlrbgePL5-NNe2nV0SDUCC5YiurIIUce85tYWJR07YQQzQjuqMqNYjQ5IZcIU6GaU5QaTIeYqnrNS4zuri2ew0cwb-wKIwRhTZ5XKuNOswqyRK8WsQ_-jxlZnJgGxendSd2znvunGTA6yHib9wkm_cDIsnLxIgPaSbWT8uIHMzkA9ekHMFj3lf5nA9kpfZOckziUit7zEmbM8gbf9ZTRv_89GNXa-xDGe77BCmMkTeB717OrmeVYVmK4mkPeK95cpX6xNWQS1uvEzyo_7J-Hw5T9LvoHNo92J_Pbl8OsruItDusLnbdhYnC3ta4R3i3on2O0fkIY7Wg |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7CBvqgpK-kdZsGFXqst37I0vqYtA0hkCXQLGxOQtbj0sVrkl266a_vyJKdOpQSSm-2bNnyaDTzjTX6BPChmHCOqEHFPE3zGP21jCtZphilpKVVGItlqVvgfDZlJzN6Oi_mWzDt1sJ4foj-h5sbGa29dgO80dbb-U-_5eNQRmOaJnPPxonBTE7HiCm3mZtwGsH2bHp-eOmXGOGNScn6Y6w0TO0JpZvBowb-6kkjr1F01u958SdQ-hgerutG3vyQi8UQ77YO6_gpLLtP9Xkq38frVTVWP--wQP4_WTyDnYBtyaFXxuewZeoX8OAszN6_hMsvZtVmftUfSetDQyoRkbUm6pY52hcuLWnckhQEw0Q53bwi1Q0574pafpNvym-5tAsXx18vPp_EYWuHWCHCoDF2jkGsOmEVMyYv0onlmlPNlU1loiWt0BLJhOsc7Y00TGNURG3JMloo7MMq34NRvazNayAanU2VlDJhVtESw0cmJTUWDZGcGJXoCHjXf0IF2nO3-8ZCDMIfKpzghBOcaAUnNhGkfc3GU3_co87BQEX6ihg2Ou7_IoL9TmdEsBbXAiFcVmDLaRbB-_4yjnM3eSNrs1zjPY74sES8ySJ45XXt9uFZUuYYt0aQ9cr3lyZv7jSZt6p1728UR6ez9vDNv7zuLTzC05DxvA-j1dXavENct6oOwmD9Bck0PVk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection%2C+localisation+and+characterisation+of+prostate+cancer+by+prostate+HistoScanning%28%E2%84%A2%29&rft.jtitle=BJU+international&rft.au=Simmons%2C+Lucy+A+M&rft.au=Autier%2C+Philippe&rft.au=Z%C3%A1t%27ura%2C+Franti%C5%9Dek&rft.au=Braeckman%2C+Johan&rft.date=2012-07-01&rft.eissn=1464-410X&rft.volume=110&rft.issue=1&rft.spage=28&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10734.x&rft_id=info%3Apmid%2F22093966&rft.externalDocID=22093966 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |